New PARP-1 inhibitors described in Xuanzhu Pharma patent
June 3, 2024
Xuanzhu Pharma Co. Ltd. has divulged poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, epilepsy, hyperlipidemia, ischemia, osteoarthritis, pain and Alzheimer’s disease.